Targeting stroke risk and improving outcomes in patients with atrial fibrillation in Latin America
Keywords:
Stroke, Atrial fibrillation, Anticoagulants, Warfarin, Risk factorsAbstract
CONTEXT AND OBJECTIVE: To examine stroke risk factors, including atrial fibrillation, management and prevention, and stroke outcomes across Latin America. DESIGN AND SETTING: Narrative review conducted at Piedmont Heart Institute, United States. METHODS: The PubMed, Embase and Cochrane databases were searched for stroke AND “Latin America” AND epidemiology (between January 2009 and March 2015). Further studies in the SciELO, World Health Organization and Pan-American Health Organization databases were used to address specific points. RESULTS: Countries categorized as low or middle-income nations by the World Bank, which includes most of Latin America, account for two-thirds of all strokes. Globally, fewer than half of patients (median treatment level: 43.9%) with atrial fibrillation receive adequate anticoagulation to reduce stroke risk, which correlates with data from Latin America, where 46% of outpatients did not receive guideline-compliant anticoagulation, ranging from 41.8% in Brazil to 54.8% in Colombia. CONCLUSIONS: Atrial fibrillation-related stroke carries a heavy burden. Non-vitamin K antagonist oral anti-coagulants provide options for reducing the risk of atrial fibrillation-related stroke. However, costeffectiveness comparisons with warfarin are warranted before observational health-economics study results can be applied clinically. Initiatives to remedy inequalities and improve access to care across Latin America should accompany risk factor modification and guideline-based prevention.
Downloads
References
Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. Neuroepidemiology. 2015;45(3):161-76.
Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990- 2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health. 2013;1(5):e259-81.
Durai Pandian J, Padma V, Vijaya P, Sylaja PN, Murthy JM. Stroke and thrombolysis in developing countries. Int J Stroke. 2007;2(1):17-26.
Feigin VL, Mensah GA, Norrving B, et al. Atlas of the Global Burden of Stroke (1990-2013): The GBD 2013 Study. Neuroepidemiology. 2015;45(3):230-6.
Institute for Health Metrics and Evaluation, Human Development Network, The World Bank. The Global Burden of Disease: Generating Evidence, Guiding Policy. Latin America and Caribbean Regional Edition. Seattle: IHME; 2013. Available from: http://www.healthdata.org/policy-report/global-burden-disease-generating-evidence-guiding-policy-%E2%80%93-latin-america-and-caribbean. Accessed in 2016 (Oct 4).
Lavados PM, Hennis AJ, Fernandes JG, et al. Stroke epidemiology, prevention, and management strategies at a regional level: Latin America and the Caribbean. Lancet Neurol. 2007;6(4):362-72.
Del Brutto OH, Santamaría M, Zambrano M, et al. Stroke in rural coastal Ecuador: a community-based survey. Int J Stroke. 2014;9(3):365-6.
Sposato LA, Coppola ML, Altamirano J, et al. Program for the epidemiological evaluation of stroke in Tandil, Argentina (PREVISTA) study; rationale and design. Int J Stroke. 2013;8(7):591-7.
Goulart AC, Bustos IR, Abe IM, et al. A stepwise approach to stroke surveillance in Brazil: the EMMA (Estudo de Mortalidade e Morbidade do Acidente Vascular Cerebral) study. Int J Stroke. 2010;5(4):284-9.
Pan American Health Organization/World Health Organization. Cardiovascular diseases in countries of the Americas. Available from: http://www.paho.org/hq/index.php?option=com_content&view=article&id=10213%3A2014-cardiovascular-diseases-in-countries-of-the-americas&catid=7237%3Adata-portal-contents&Itemid=41160&lang=en. Accessed in 2016 (Oct 4).
GBD 2013 DALYs and HALE Collaborators, Murray CJ, Barber RM, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145-91.
Nicoletti A, Sofia V, Giuffrida S, et al. Prevalence of stroke: a door-to-door survey in rural Bolivia. Stroke. 2000;31(4):882-5.
GBD 2013 Risk Factors Collaborators, Forouzanfar MH, Alexander L. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(10010):2287-323.
Cantu-Brito C, Majersik JJ, Sánchez BN, et al. Door-to-door capture of incident and prevalent stroke cases in Durango, Mexico: the Brain Attack Surveillance in Durango Study. Stroke. 2011;42(3):601-6.
Lavados PM, Sacks C, Prina L, et al. Incidence, 30-day case-fatality rate, and prognosis of stroke in Iquique, Chile: a 2-year community-based prospective study (PISCIS project). Lancet. 2005;365(9478):2206-15.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-8.
Healey JS, Oldgren J, Parekh A, et al. RE-LY AF: Global variations in the 1-year rates of death and stroke in 15,432 patients presenting to the emergency department with atrial fibrillation in 47 countries: The RE-LY AF Registry. In: ESC Congress 365, 2012;[abstract 711005-6]. Available from: http://www.escardio.org/Congresses-%26-Events/ESC-Congress/Congress-resources/Session-Reports/Reports-2012/RE-LY-AF-Global-variations-in-the-1-year-rates-of-death-and-stroke-in-15-432-pa#. Accessed in 2016 (Oct 4).
Cubillos L, Haddad A, Kuznik A, Mould-Quevedo J. Burden of disease from atrial fibrillation in adults from seven countries in Latin America. Int J Gen Med. 2014;7:441-8.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.
Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-17.
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.
Murray CJ, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ. 1994;72(3):495-509.
World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization; 2008. Available from: http://www. who.int/healthinfo/global_burden_disease/GBD_report_2004update_ full.pdf. Accessed in 2016 (Oct 4).
Christensen MC, Previgliano I, Capparelli FJ, et al. Acute treatment costs of intracerebral hemorrhage and ischemic stroke in Argentina. Acta Neurol Scand. 2009;119(4):246-53.
Christensen MC, Valiente R, Sampaio Silva G, et al. Acute treatment costs of stroke in Brazil. Neuroepidemiology. 2009;32(2):142-9.
Pan American Health Organization (PAHO). Pan American Sanitary Bureau, Regional Office of the World Health Organization. Health in the Americas. PAHO Scientific and Technical Publication No. 622, 2007. Available from: http://www1.paho.org/hia/index.html. Accessed in 2016 (Jun 23).
Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation. 2011;124(3):314-23.
Lotufo PA. Stroke in Brazil: a neglected disease. Sao Paulo Med J. 2005;123(1):3-4.
Abe IM, Lotufo PA, Goulart AC, Benseñor IM. Stroke prevalence in a poor neighbourhood of São Paulo, Brazil: applying a stroke symptom questionnaire. Int J Stroke. 2011;6(1):33-9.
Kawabata-Yoshihara LA, Benseñor IM, Kawabata VS, et al. Prevalência de Achados eletrocardiográficos no paciente idoso: estudo envelhecimento e saúde de São Paulo [Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging & health study]. Arq Bras Cardiol. 2009;93(6):651-6.
Fernandes TG, Benseñor IM, Goulart AC, et al. Stroke in the rain forest: prevalence in a ribeirinha community and an urban population in the Brazilian Amazon. Neuroepidemiology. 2014;42(4):235-42.
Lotufo PA, Goulart AC, Fernandes TG, Benseñor IM. A reappraisal of stroke mortality trends in Brazil (1979-2009). Int J Stroke. 2013;8(3):155-63.
Chor D, Pinho Ribeiro AL, Sá Carvalho M, et al. Prevalence, Awareness, Treatment and Influence of Socioeconomic Variables on Control of High Blood Pressure: Results of the ELSA-Brasil Study. PLoS One. 2015;10(6):e0127382.
Faerstein E, Chor D, Werneck GL, Lopes CS, Kaplan G. Raça e racismo percebido, escolaridade e hipertensão em funcionários públicos brasileiros: estudo Pró-Saúde [Race and perceived racism, education, and hypertension among Brazilian civil servants: the Pró-Saúde study]. Rev Bras Epidemiol. 2014;17(suppl 2):81-7.
Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27(10):1760-4.
Cantú-Brito C, Ruiz-Sandoval JL, Murillo-Bonilla LM, et al. The first Mexican multicenter register on ischaemic stroke (the PREMIER study): demographics, risk factors and outcome. Int J Stroke. 2011;6(1):93-4.
Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):429S-56S.
Ogilvie IM, Newton N, Weiner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638-45.e4.
Suarez J, Piccini JP, Liang L, et al. International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. Am Heart J. 2012;163(5):804-11.
European Heart Rhythm Association; European Association for Cardio- Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429.
European Heart Rhythm Association; European Association for Cardio- Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360-420.
Culebras A. Stroke is a catastrophic disease in Latin America. Neurology (International Newsletter). 2005;64(8):25A-26A. Available from: http://www.neurology.org/content/64/8/25A.short?sid=6345aa61-38b3-486d-8e9d-89e4ef6cc939. Accessed in 2016 (Oct 24).
World Health Organization. STEPwise approach to stroke surveillance. Available from: http://www.who.int/chp/steps/stroke/en/. Accessed in 2016 (Oct 4).
Orduñez-García PO, Iraola-Ferrer MD, Taboada RB. Cuba: better care for stroke. BMJ. 2006;332(7540):551.
Cabral NL, Volpato D, Ogata TR, et al. Fibrilação atrial crônica, AVC e anticoagulação: sub-uso de warfarina? [Atrial fibrillation, stroke and anticoagulation: under-use of warfarin?] Arq Neuropsiquiatr. 2004;62(4):1016-21.
Mesas CE, Veloso HH, De Paola AA. Anticoagulation for atrial fibrillation: underutilization in a Brazilian tertiary outpatient clinic. Clin Cardiol. 2004;27(11):592-3.
Aburto-Murrieta Y, Arauz-Góngora AA, Murillo-Bonilla LM, López- Gómez M. [Non-valvular atrial fibrillation and completed stroke: factors determining mortality, recurrence and prognosis after a first event in the Mexican population]. Rev Neurol. 2005;40(5):269-73.
American Heart Association. American Stroke Association. Scaling up stroke prevention and treatment in the Americas: Declaration of Santiago de Chile. October 31, 2015. Available from: http://www. strokeassociation.org/idc/groups/stroke-public/@wcm/@private/@ hcm/@sta/documents/downloadable/ucm_479447.pdf. Accessed in 2016 (Oct 4).
Biskupiak J, Ghate SR, Jiao T, Brixner D. Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation. J Manag Care Pharm. 2013;19(9):789-98.
